Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorRelapsed or Refractory Lymphomas
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06132503
- Locations
- ๐บ๐ธ
Cancer and Blood Specialists Clinic, Los Alamitos, California, United States
๐บ๐ธFlorida Cancer Specialists, Lake Mary, Florida, United States
๐บ๐ธSCRI Oncology Partners, Nashville, Tennessee, United States
Study of LP-184 in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorGBMTNBC - Triple-Negative Breast CancerDDR Gene MutationNSCLCPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT05933265
- Locations
- ๐บ๐ธ
Highlands Oncology Group, Springdale, Arkansas, United States
๐บ๐ธCancer and Blood Specialty Clinic, Los Alamitos, California, United States
๐บ๐ธNorthwest Oncology & Hematology, Rolling Meadows, Illinois, United States
A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05456256
- Locations
- ๐บ๐ธ
Los Angeles Cancer Network, Fountain Valley, California, United States
๐ฏ๐ตHokkaido Cancer Center, Sapporo-Shi, Hokkaido, Japan
๐ฏ๐ตKanagawa Cancer Center Hospital, Yokohama-Shi, Kanagawa, Japan
ยฉ Copyright 2025. All Rights Reserved by MedPath